The government has unveiled a transformative initiative that will empower millions of NHS patients to find and join clinical trials via the NIHR’s “Be Part of Research” portal within the NHS App.
On Wednesday (12 May), the CDC announced that the Pfizer vaccine could now be given to 12-15 year olds - effective immediately for 17 million adolescents.
The CureVac mRNA vaccine is currently in final stages of clinical trials - but it is expected to perform like Pfizer and Moderna, with the bonus of surviving at ordinary refrigeration temperatures.
Pfizer could make their COVID vaccine available to 12-year-olds in Europe from June, after clinical trials in March showed 100% efficiency for those aged 12 to 15.
The study found that missing a second COVID dose could "prolong" the pandemic, with more than 5 million people in the US not taking their scheduled dose.
The city of Manaus was hit so overwhelmingly by the Brazilian COVID mutation, it was believed that 75% of the population had COVID - what new truths are scientists learning about this powerful variant?
New data from the UK's vaccination programme suggests that one in four people get Pfizer and AstraZeneca vaccine side effects - with most peaking in the first 24 hours, then gone in two days.
Pfizer CEO Albert Bourla suggested that fully vaccinated people would need their third vaccine dose, maybe 12 months after they got their second - the EU is currently in talks to secure a further 1.8 billion doses.
Researchers in the UK started a clinical trial on mixing vaccines in February - today (14 April) a new study will look into mixing Moderna and Novavax doses.
US authorities paused the use of the Johnson & Johnson single dose vaccine as they look into six cases of blood clots that developed in women aged between 18 and 48.
Uninfected people lived with one infected individual as part of the study - the COVID antibody drug gave them 72% protection against catching the virus themselves.
Today (8 April) it was revealed that over 700,000 AstraZeneca doses manufactured in the UK are being sent to Australia - with a confirmed 300,000 vaccines in Sydney at the end of February.
Real-world use of the Moderna and Pfizer vaccines in the United States reveals that both are working at 90% efficacy - with data pointing to one dose being capable of 80% protection.
Tore K Kvien & Guro L Goll argue that biosimilars are an opportunity for improving access to treatment & reducing cost and provide comment on the NOR-SWITCH study.
